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Currently, schizophrenia is considered a multifactorial disease. Over the past 50 years,
many investigators have considered the role of toxic free radicals in the etiology of
schizophrenia. This is an area of active research which is still evolving. Here, we review the
recent data and current concepts on the roles of nitric oxide (NO) and related molecules
in the pathogenesis of schizophrenia. NO is involved in storage, uptake and release
of mediators and neurotransmitters, including glutamate, acetylcholine, noradrenaline,
GABA, taurine and glycine. In addition, NO diffuses across cell membranes and activates
its own extrasynaptic receptors. Further, NO is involved in peroxidation and reactive
oxidative stress. Investigations reveal significant disturbances in NO levels in the brain
structures (cerebellum, hypothalamus, hippocampus, striatum) and fluids of subjects
with schizophrenia. Given the roles of NO in central nervous system development, these
changes may result in neurodevelopmental changes associated with schizophrenia.
We describe here the recent literature on NOS gene polymorphisms on schizophrenia,
which all point to consistent results. We also discuss how NO may be a new target for
the therapy of mental disorders. Currently there have been 2 randomized double-blind
placebo-controlled trials of L-lysine as an NOS inhibitor in the CNS.
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Introduction
The pathogenesis of schizophrenia. Basic theories of development of the
disease
Schizophrenia is a severe mental disease with a chronic course, mainly manifesting at a young age
(Tien and Eaton, 1992). According to various data, about 0.3–0.7% of the world’s population suffer
from schizophrenia (McGrath et al., 2008; Tandon et al., 2008). Aetiopathogenetic mechanisms of
this disease are still unclear (Eaton et al., 1995; Keshavan et al., 2013). There is also a generality
of symptoms between schizophrenia proper, schizoaffective disorder, bipolar affective disorder
(Rimol et al., 2010; Keshavan et al., 2013). In the present circumstances, there is a need for a more
precise answer to the question of what underlies the pathogenesis of schizophrenia and defines its
uniqueness.
Currently, schizophrenia is considered a multifactorial disease. Up to 80% of cases of
schizophrenia are associated in one way or another with genetic factors (Sullivan et al., 2003;
Käkelä et al., 2014). Recent GWAS-analyses have revealed genes associated with schizophrenia
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(for example, NRGN, TCF4, and TSNARE1). The functions of
some genes are still unknown (Stefansson et al., 2009; Sleiman
et al., 2013). Therefore, the known genetic risk cannot yet predict
the cause of the disease and what underlies its pathogenesis.
There are several basic hypotheses regarding the development of
schizophrenia. The earliest hypothesis postulates that the cause
of the disease consists of dopamine metabolism disturbance,
namely in the increase in its synthesis (van Rossum, 1966; Creese
et al., 1976). The second version of the same hypothesis argues
that dopamine metabolism is disturbed in two directions—the
level of the neuromediator increases in subcortical (striatum)
and decreases in prefrontal structures of the brain (Scatton
et al., 1982). In particular, the hypothesis attempted to associate
negative symptoms with low-dopaminergiñ state (Davis et al.,
1991). Finally, the dopaminergic theory was reduced to the
concept of “a final general way” that is interpreted as an
influence of various factors, including exogenous factors, on
presynaptic dopamine neurotransmission in striatum and that
leads to development of the disease (Howes and Kapur, 2009).
It is possible to consider the recognition of the role of glutamate
(NMDA-receptors) and gamma-aminobutyric acid (GABA) as
an addition to the dopaminergic theory of schizophrenia
in its pathogenesis (Timms et al., 2013; Hu et al., 2014).
Another hypothesis is associated with detection of development
disturbances of some brain areas in schizophrenics (Pino et al.,
2014). The latter hypothesis is backed by a lot of evidence
(Howes et al., 2011; Jenkins, 2013), especially in the aspect of
neurocognitive impairment (Dickson et al., 2012). A related point
of view is a neurodegenerative theory of the disease. The essence
of the theory is that schizophrenia is not a consequence of the
improper development, but of gradual progressive disintegration
of the nervous tissue in the brain (Hardy and Gwinn-Hardy,
1998). In the latter two theories, the important role is attributed
to exogenous factors (Jenkins, 2013). Taking into account
available evidence, it is possible to assume that etiopathogenesis
of schizophrenia involves influence of the environment on the
organism both during the process of development and after
its completion. Of major significance are alterations in gray
matter, occurring in the critical periods of development—during
childbirth, at adolescence (Clarke et al., 2011; Hart et al., 2013).
But pathogenicmechanismswhich lead to described disturbances
are the subjects of discussions. Publications of recent years state
the undoubted role of inflammation and oxidative stress in
pathogenesis of mental diseases, especially schizophrenia (Song
et al., 2013; Bergink et al., 2014; Haller et al., 2014). In numerous
investigations, associations between existence of disease and
activation of immune markers in the patient have been found
(Song et al., 2013; Bergink et al., 2014; de Witte et al., 2014).
Some authors consider infectious agents as etiologic factors
(Brown and Derkits, 2010). But, irrespective of its cause, the
inflammatory process is associated with oxidative stress which
leads to alterations of the tissues, some of which are irreversible
(Bitanihirwe and Woo, 2011).
Role of Oxidative Stress of CNS in Schizophrenia
Development
Role of toxic free radicals in the etiology of schizophrenia was
first investigated more than 50 years ago (Hoffer et al., 1954). As
of now, markers of oxidative stress are revealed in patients with
schizophrenia, reliablymore often than in the general population.
One of the latest papers is a meta-analysis by Flatow et al.
(2013), where 44 investigations are considered and a conclusion
about reliability of association of markers of oxidative stress
with psychosis and schizophrenia existence in patients is drawn
(Flatow et al., 2013). Let us consider in more detail what is
included in concept of oxidative stress and what its potential role
in schizophrenia development is.
The Structure of Oxidative Stress
Free Radicals
Oxidative stress is a state during which the balance between
the system of antioxidants and level of free radicals, able
to damage tissues, is disturbed (Kohen and Nyska, 2002).
Synthesis of free radicals occurs during physiological oxidation-
reduction processes (Berg et al., 2004). Free radicals are as
follows: active forms of oxygen (reactive oxygen species—ROS),
active forms of nitrogen—(RNitrogenS—RNS), carbon-centered
radicals and sulfur-centered radicals (Miller et al., 1990). ROS
is the most significant system of free radicals, because it shows
the double role of oxygen in the organism (oxygen paradox)—
this element is involved almost in all vital processes, and at the
same time its active forms, leading to damage of tissues, are
formed (Davies, 1995). Hydrogen peroxide (H2O2), superoxide-
radical (O2·−) and hydroxide-radical (OH·) belong to ROS.
Nitrogen-containing factors of oxidation: nitrogen oxide (NO),
peroxynitrite (ONOO·) and nitrogen dioxide (N2O2). Nitric
oxide is able to form hydroxyl radicals (at the expense of
the unpaired electron) and to turn into nitrogen dioxide (Wu
et al., 2013). During maintenance of balance, free radicals
carry out important functions in the organism: they protect
cells against infectious and foreign agents, serve as secondary
mediators in regulation of activity of cardiovascular system,
are involved in processes such as maintenance of intracellular
level of calcium, phosphorylation/dephosphorylation of proteins
and activation of transcription factors (Halliwell, 2007; Valko
et al., 2007; Ataya et al., 2011; Wu et al., 2013). Nitric oxide
possesses properties of both pro- and antioxidant. So, it is
able to stimulate peroxidation of lipids and mediate antioxidant
reactions in cellular membranes at the same time (Radi et al.,
1991). NO is able to bind with peroxyl radicals, interrupting the
oxidative process circuit. However, free nitric oxide can bind with
superoxide, forming highly toxic peroxynitrite (Bitanihirwe and
Woo, 2011). The imbalance of antioxidants and free radicals leads
to damage of cellular structures: proteins, lipids, DNA (Kohen
and Nyska, 2002).
Antioxidants
The antioxidants, serving for maintenance of oxidation-
reduction balance, are as follows: superoxide dismutase (SOD),
catalase (CAT) and glutation peroxidase (GSH-Px) (Yao and
Keshavan, 2011). The three enzymes act in cooperation, blocking
formation of free radicals at different stages of their metabolism.
Hydrogen peroxide formed by SOD is decomposed into water
and oxygen by catalase. Breakage of this mechanism of protection
leads to activation of peroxidation of lipids. GSH-Px is able
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to stop the process at this stage with the use of the transfer
of toxic hydroperoxides into less active forms. Disturbance of
activity of any of three enzymes results in increased vulnerability
of membranes of cells for damage by free radicals (Smith,
1992). Albumin, vitamin E (α-tocopherol), uric acid, bilirubin,
ascorbic acid, and thioredoxin belong traditionally to nonenzyme
antioxidants (Yao et al., 2000). Nonenzyme antioxidants from
plasma of blood make the basic contribution to counteraction to
oxidative stress (Yao et al., 2000; Reddy et al., 2003; Reddy, 2011).
Oxidative Stress and Schizophrenia
The role of oxidative stress in the development of mental
diseases is still debated despite decades of investigations in
this direction. The different approaches of researchers appear
to be a likely reason for these debates. Free radicals dissociate
very quickly and measuring their number in live organisms
is difficult. Thus, indirect methods such as measurement of
activity of basic antioxidant enzymes as well as the quantitative
identification of peroxidation products in biological mediums are
more widespread (Wu et al., 2013). The role of oxidative stress is
actively studied in the terms of neuropsychiatric diseases, such as
depression (Moylan et al., 2014; Rodrigues et al., 2014), bipolar
disorder (Bauer et al., 2014), Alzheimer’s disease (Rodrigues
et al., 2014), and Huntington’s chorea (Ciancarelli et al., 2014).
In this review we will go into detail on schizophrenia, without
mentioning the investigations, covering other diseases.
Indicators of Activity of Antioxidant Enzymes in
Schizophrenia
As mentioned above, the measurement of antioxidant enzymes is
complicated due to their properties. However, numerous studies
have been carried out in this field. Unfortunately, an unequivocal
answer still has not been obtained. Studies of SOD activity in
patients with schizophrenia are met in literature more often
than that of other enzymes. Many authors have concluded that
activity of this enzyme is reduced in patients with schizophrenia
(Ben Othmen et al., 2008; Dadheech et al., 2008; Raffa et al.,
2009, 2012a; Gonzalez-Liencres et al., 2014; Wu et al., 2014).
However, there are results for both hyperactivity of superoxide
dismutase in this disease (Wu et al., 2012) and unaltered activity
as compared to controls (Raffa et al., 2011; Srivastava et al.,
2001). Results regarding measuring levels of glutation peroxidase
(Raffa et al., 2009, 2012b; Dietrich-Muszalska and Kwiatkowska,
2014) and catalase (Ben Othmen et al., 2008; Raffa et al., 2011,
2012b) are contradictory. This is covered in more detail in
relevant literature reviews (Yao and Keshavan, 2011; Wu et al.,
2013). To present, 2 meta-analyses of research of activity of
antioxidants in patients with schizophrenia have been carried
out. Zhang et al. (2010) concluded that oxidative stress in
schizophrenia really takes place. However, decrease in SOD
activity in this disease has been recognized as reliable, levels
of CAT and GSH-Px have not shown sufficient statistical effect
(effect size). Authors indicate that considerable heterogeneity
of the carried-out analysis means an influence of unaccounted
factors on the obtained result (Zhang et al., 2010). Meta-analysis
by Flatow et al. (2013), mentioned above, has confirmed decrease
in SOD activity in patients with schizophrenia according to
cross-sectional investigations in the first psychotic episode, in
remission and in the state of exacerbation. But considerable
additions to results of the previous systematic review have been
made: activity of catalase was reliably decreased in patients with
initial episode (first episode psychosis) (p < 0.01) and reliably
increased in patients in remission (p < 0.01) as compared with
controls. Authors have assumed that the total antioxidant level
is a situationally conditioned marker, labile under the influence
of the mental state of the patient. But enzyme SOD, which has
shown, irrespective of disease’s stage, decreased as compared with
healthy controls activity level, can be considered as a typical trait
of patients with schizophrenia (Flatow et al., 2013).
Peroxidation products were also studied as markers of
oxidative stress. The basic objective of these investigations—
malondialdehyde (MDA), identified with use of measuring of
the content of thiobarbituric acid reactive substance (TBARS)
(Vasankari et al., 1995). Investigations are so far not plentiful.
Gubert et al. (2013) have found a reliable increase in the level of
TBARS in patients with schizophrenia as compared with controls
(Gubert et al., 2013). This result coincides with previously
obtained results (Zhang et al., 2006; Dietrich-Muszalska and
Kontek, 2010), including meta-analysis by Zhang et al. (2010). In
addition, seasonal dynamics of level of metabolites in plasma of
patients with schizophrenia have been followed up: in summer,
contents of MDA in serum exceeds winter indices by 33,9%
(Morera et al., 2009). Besides MDA, isoprenes, in particular 8-
isoPGF2 alpha, were considered as biomarkers of peroxidation
(Dietrich-Muszalska and Olas, 2009). However, there is still not
enough of an evidence base for association of 8-isoPGF2 alpha
with schizophrenia.
Indices of Activity of Plasma Antioxidants in
Schizophrenia
Asmentioned above, plasma antioxidants make the basic (>85%)
contribution to the fight against oxidative stress (Wayner et al.,
1987; Reddy et al., 2003; Reddy, 2011). For patients with
schizophrenia, it is shown that in the first psychotic episode,
plasma levels of α-tocopherol (Dadheech et al., 2008), ascorbic
acid decrease (Suboticanec et al., 1990; Dadheech et al., 2008),
level of thioredoxin increases (Zhang et al., 2009; Owe-Larsson
et al., 2011). In opinion of Zhang et al. (2009), in patients
with schizophrenia, the level of thioredoxin is close to that
of healthy controls (Zhang et al., 2009). The same authors, in
2013, have confirmed that the plasma level of thioredoxin in
patients with schizophrenia does not exceed reliably healthy
controls and is associated with the level of cognitive abilities.
It is shown that the level of thioredoxin is reliably decreased
in patients with attention deficit disorder (Zhang et al., 2013).
Bilirubin, uric acid and albumin have also been measured in
patients with schizophrenia. Decreased plasma levels in the first
psychotic episode as compared with controls have been noted
(Yao et al., 1998, 2000; Reddy et al., 2003; Pae et al., 2004). It is
interesting to note that attempts to associate separate symptoms
of schizophrenia with levels of plasma antioxidants and the use
of these symptoms as a diagnostic and predictive marker have
taken place (Yao et al., 2012). Indeed, the total antioxidative
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status (TAS) is reliably low in the first psychotic episode,
negatively correlating with negative symptoms according to
PANSS (Positive and Negative Syndrome Scale) (Pazvantoglu
et al., 2009; Li et al., 2011). The assumption has been made
that oxidative stress arises during onset of the disease and
exerts essential impact on the further course of schizophrenia,
especially on the formation of negative symptoms. Preliminary
results of the investigation by Albayrak et al. (2013) have
revealed that patients with persistent negative symptoms (deficit
schizophrenia) have a decreased total antioxidative potential and,
at the same time, their index of oxidative stress is increased as
compared with healthy controls and patients with non-deficit
schizophrenia (Albayrak et al., 2013).
Influence of oxidative stress on the course of schizophrenia
is confirmed by studies which show that treatment with
antipsychotics leads to considerable alterations of the oxidation-
reduction balance. However, results indicate otherwise. There
is a point of view that antipsychotic therapy decreases the
level of oxidants in the organism (Tsai et al., 2013). At the
same time, pro-oxidant activity is attributed to Haloperidol
in vitro as compared with Quetiapine and Olanzapine (Dietrich-
Muszalska, 2011). Clozapine has contradictory properties
regarding influence on oxidative stress (Miljevic et al., 2010; Gilca
et al., 2014). But despite all contradictions, an undoubted effect of
treatment with antipsychotics on indicators of oxidative stress is
confirmed.
It is clear from the above paragraphs that there is a sufficient
number of markers of oxidative stress, and this is an almost
unlimited field for research. However, in this review we would
like to consider the system of nitric oxide and related molecules
within the pathogenesis of schizophrenia in more detail.
Nitric Oxide in Pathogenesis of
Schizophrenia
Biochemistry of Nitric Oxide in the Organism and
CNS. The Interactions of NO with other Factors of
Oxidative Stress
Before considering the works devoted to the role of nitric oxide
in development of schizophrenia, it is necessary to understand its
biochemistry, biological parameters and functions.
Nitric oxide is involved in many processes occurring in the
brain: regulation of synaptic plasticity (Hölscher and Rose, 1992),
release of mediators (Lonart et al., 1992), and development of
nervous tissue (Gibbs, 2003). Below we describe the main points
of NO’s biochemistry and its role in CNS.
Biochemistry of NO
Nitric oxide (NO) is released during conversion of L- arginine
into L-citrulline under influence of nitric oxide synthase (NOS)
(Ghafourifar and Cadenas, 2005). The reaction proceeds in
the presence of oxygen, NADPH-containing flavin adenine
dinucleotide (FAD), flavin mononucleotide (FMN), heme, thiol
and tetrahydrobioprotein as cofactors (Akyol et al., 2004; Giraldi-
Guimarães, 2004). NO has a very short half-life period—several
seconds in water medium. However, placed under anaerobic
conditions, this radical does not decompose for more than
15 s. In mixed water and lipid medium, nitric oxide is easily
able to penetrate cytoplasmic membranes (Chiueh, 1999; Valko
et al., 2007; Babicová et al., 2013). Free radical NO at the
expense of unpaired electron possesses toxic potential. So, in
high concentrations, nitric oxide reacts with superoxide-radical,
forming peroxynitrite (ONOO) (Ridnour et al., 2004; Blaise
et al., 2005; Wu et al., 2013), a powerful oxidant at physiological
pH (Noack et al., 1999). Peroxynitrite is able to trigger lipid
peroxidation and destruction of proteins, amino acids, nucleic
acids; this leads to suppression of activity of enzymes and
autoxidation of dopamine. This mechanism has been studied
in the context of development of neurodegenerative diseases,
in particular, Parkinson’s disease (Tohgi et al., 1998). However,
peroxynitrite quickly turns into stable nitrate NO3- (Tohgi et al.,
1998; Antunes et al., 2005). Toxicity of NO increases during low
concentrations of L- arginine, as in this case superoxide-radical is
generated by NOS (Xia et al., 1998; Akyol et al., 2004). The state
in which formation of reactive compounds of nitrogen (RNS)
exceeds their neutralization is called nitrosative stress (Ridnour
et al., 2004; Valko et al., 2007). It is worth mentioning that
most physiological effects of NO are mediated by a radical that
quickly binds with complexes: Fe2+-Haem. The reaction product
is {Fe2+-NO·}. This compound allows avoiding reactions of
oxidative stress (Archer, 1993; Valko et al., 2007).
NO-Synthase
The enzyme generating nitric oxide is represented in the
organism in the kind of three isoforms: neuronal (nNOS),
inducible (iNOS), and endothelial (eNOS).
Nitric oxide synthesized by endothelial NO synthase
renders vasodilatating, anti-inflammatory, antithrombotic and
antiproliferative effects. Endothelial NO synthase itself is located
in the cells of endothelium (Furchgott and Zawadzki, 1980;
Endres et al., 2004). Synthesis of nitric oxide by endothelial NOS
is regulated by several factors: calcium-dependent calmodulin,
caveolin-1 and 3, B2-receptors of bradykinin, A1-receptors
of angiotensin, steroid hormones (Fleming and Busse, 2003;
Gwathmey et al., 2012; Kypreos et al., 2014). It has been
revealed that disturbance of synthesis and release of nitric oxide
(eNOS is responsible for this) leads to increased aggregation of
thrombocytes, inflammation of endothelium and as a result—to
the disturbance of cerebral blood flow (Diodati et al., 1998; Toda
et al., 2009; Austin et al., 2013). The importance of this enzyme
is generally considered in the context of neurodegenerative
diseases (Alzheimer’s disease etc.) (Toda, 2012). However, below
we will introduce recent investigations about possible role of
eNOS in pathogenesis of schizophrenia.
iNOS enzyme plays an essential role in inflammatory
processes during damage or infectious impairment of tissues
(Lerouet et al., 2002). In the brain tissue, this type of NO synthase
is located in microglia, endothelium of brain vessels, infiltrating
macrophages and T-lymphocytes. Unlike eNOS and nNOS, this
isoform is calcium-independent (Possel et al., 2000; Bernstein
et al., 2005a). Microglia produces neuro-toxic nitric oxide
(Lazzaro et al., 2014). Regulation of iNOS gene transcription
depends on cAMP concentration.When level of cAMP increases,
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cellular reactions of inflammation are blocked (Markovic et al.,
2003; Valko et al., 2007). NO, generated by inducible NOS, is
involved in pathogenesis of Alzheimer’s diseases, septic shock,
multiple sclerosis and brain ischemia (Wass et al., 2008; Ghasemi
and Fatemi, 2014).
Neuronal NOS (nNOS) generates up to 90% of nitric oxide
in the brain of mammals (Hara et al., 1996). Besides neurons,
nNOS is found in skeletal muscles, myocardium and smooth
muscle tissue (McConell et al., 2007; Seddon et al., 2007). This
enzyme is linked with NMDA receptors by means of the specific
domain. This allows for activation the NO synthesis in response
to influx of calcium ions into the cell after excitement of receptors
(Girouard et al., 2009). Synthesis of this enzyme in the neuron
is determined by the function carried out by the cell. It has
been shown that nNOS influences the development of neuronal
structures (Chen et al., 2004). nNOS distribution in neurons
depends on their localisation. The highest concentrations of
the enzyme are found in substantia innominata, septum, cortex
cerebelli, hypothalamus, subthalamus. The lowest concentrations
are found in corpus callosum, thalamus, occipital cortex, dentate
nucleus (Blum-Degen et al., 1999). In addition to neurons, nNOS
can be present in the cells of glia and blood vessels of the
brain (Kawakami et al., 1998). Sufficiently detailed review of
metabolism of nNOS has been published by Zhou and Zhu
(2009).
Role of Nitric Oxide in CNS
NO is the second mediator of activation of NMDA receptors
(subtype of glutamatergic receptors). In norm, during activation
of these receptors by glutamate, calcium influx into the
cell is stimulated, and NO synthase forms nitric oxide that
intermediately activates guanylate cyclase and causes increased
cGMP synthesis (Szabadits et al., 2011). It has been identified
that the concentration of NO reflects activity of glutamatergic
neurotransmission (Akyol et al., 2004). However, other receptors
of glutamate (for example, AMPA) also are able to generate
NO (Zhou et al., 2006). This pathway modulates the release of
glutamate and dopamine (Hoque et al., 2010; Szabadits et al.,
2011). In addition to glutamate, NO is involved in storage, uptake
and release of mediators, such as acetylcholine, noradrenaline,
GABA, taurine and a glycine (Kraus and Prast, 2001; Boehning
and Snyder, 2003). In addition, nitric oxide is a mediator able
to activate its own extrasynaptic receptors, located some distance
from the place of NO synthesis (Kiss and Vizi, 2001). It is known
that nitric oxide is involved in the process of development of the
nervous system (Lonart et al., 1992; Gibbs, 2003; Bernstein et al.,
2011). Recent experimental studies have increased the evidence
base of this statement. So, it has been established that nNOS-
containing neurons actively participate in the rostral path of
migration of neuroblasts, creating new synaptic connections and
considerably influencing the neurogenesis (Blasko et al., 2013).
Migration of astrocytes is also determined by release of NO under
action of iNOS, according to an investigation by Wang et al.
(2011). Nitric oxide is recognized also as an important factor of
the formation of synapses and the growth of nervous fibers (Duan
et al., 2012; Cooke et al., 2013; Upreti et al., 2013). It is worth
repeating that NO influences the development of nervous tissue
by regulation of cerebral blood flow (Furchgott and Zawadzki,
1980; Endres et al., 2004; Virarkar et al., 2013).
Role of Nitric Oxide and Related Molecules in
Schizophrenia Development
As has been mentioned above, nitric oxide can also act as a free
radical. To this end, it is worth considering the participation of
NO in the pathogenesis of schizophrenia.
For the first time, Russian scientists Averbukh et al. (1966) and
Bul’ba et al. (1968) have suspected that there is an association
between NO and the onset of schizophrenia (Averbukh et al.,
1966; Bul’ba et al., 1968). However, this molecule has been most
actively investigated in the aspect of mental diseases during the
last 25 years. Identification of activity of nitric oxide in tissues
and biological media can be carried out by means of detection of
NO-synthase, because the NO molecule has a very short period
of existence (Babicová et al., 2013).
Post-Mortem Studies
Researchers who have found an increased level of nitric oxide
in post-mortem brain tissue (Yao et al., 2004; Lauer et al., 2005;
Cui et al., 2010) and in plasma (Zhang et al., 2010; Flatow
et al., 2013) of schizophrenics also support the existence of an
association between NO synthase activity and schizophrenia.
Actually, the level of nNOS differs in patients with schizophrenia
and healthy controls (Akyol et al., 2004). However, this issue
is disputed. In the cortex of the cerebellum, the level of nNOS
did not differ between patients with schizophrenia and healthy
controls in the investigation byDoyle and Slater (1995). However,
there is also other data—increased NO synthase activity has been
detected in Purkinje cells and dentate nucleus of patients with
schizophrenia but not with depression (Bernstein et al., 2001).
With regard to the neocortex, data about presence of NO synthase
are inconsistent. There is data about increasing of expression
of nNOS in prefrontal cortex in schizophrenia (Baba et al.,
2004), but a disproof of these findings was also published (Xing
et al., 2002). Interesting data were obtained during investigations
of neurons of hypothalamus. So, the decreasing of nNOS-
containing neurons has been revealed in periventricular nucleus
of patients with schizophrenia and affective disorders (Bernstein
et al., 1998). Decreased number of neurons with nNOS in
suprachiasmatic nucleus has been also described (Bernstein et al.,
2005b, 2010). At the same time, the expression level of enzyme
was not disturbed (Bernstein et al., 2000). It is known that NO
in the hypothalamus regulates synthesis and release of hormones
which regulate hypothalamic-pituitary-adrenal system (HPAS):
oxytocin, vasopressin, corticoliberin (Bernstein et al., 1998).
Disturbed production and release of these peptides leads to HPAS
hyperactivation in patients with schizophrenia (Ryan et al., 2004).
The findings indicate that the disturbed NO synthesis by means
of influence on hormonal balance can lead to the development
of mental diseases. This statement is also confirmed by the fact
that improvement of the course of depression and other mental
diseases after electroconvulsive therapy is conditioned by the
effect of hypothalamic NO. Rosen et al. (2003) have shown that
nitric oxide during electroconvulsive therapy exerts an essential
influence on cerebral blood flow, long-term potentiation of
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NMDA receptors, and activity of HPAS (Rosen et al., 2003).
In addition to hypothalamic structures, there are data about
the change of NO activity in striopallidar system (Lauer et al.,
2005), nucleus caudatus, and hippocampus in mental disorders.
In one instance, based on study of 15 postmortem samples of the
brain of patients with schizophrenia, the decrease in the number
of nNOS-containing neurons in lateral part of the lenticular
nucleus has been found (Fritzen et al., 2007). The increased
activity of nitric oxide in neurons of nucleus caudatus has been
also shown for patients with schizophrenia (Yao et al., 2004).
Research of the hippocampus indicated differences between
healthy controls from schizophrenics. It was revealed that NO-
synthase been activated mainly in the right hippocampus of
schizophrenics (Kristofiková et al., 2008). Although currently
there are less post-mortem studies, experimental studies on
modeling of schizophrenia confirm increase in the concentration
of NO-synthase and activation of microglial inflammation
in hypothalamus (Jing et al., 2013; Ribeiro et al., 2013).
Researchers who used phencyclidine for modeling of symptoms
of schizophrenia in animals confirm the alteration of metabolism
of L-arginine and as a result—high concentration of NO in
brain structures. An association between altered content of
nitric oxide and disturbances of behavior and cognition was
found (Pålsson et al., 2010; Finnerty et al., 2013; Knox et al.,
2014).
NO Levels in Biological Fluids
Measurement of NO level in biological fluids of schizophrenics
has also been carried out. Level of NOS and NO metabolites
in the blood of patients with schizophrenia and depression has
been found by various investigators, both as increased (Yilmaz
et al., 2007; Akpinar et al., 2013) and as decreased (Srivastava
et al., 2001). In themeta-analysis byMaia-de-Oliveira et al. (2012)
it has been shown that the level of nitric oxide does not differ
significantly between patients with schizophrenia and healthy
controls. However, a reliably higher level of NO was found in
patients treated with antipsychotics, which suggests the influence
of these drugs on the metabolism of NO synthase (Maia-de-
Oliveira et al., 2012). In addition to blood, attention of the
investigators was drawn by cerebrospinal fluid. But articles on
this topic are scarce, and results are not consistent. According
to the investigation by Ramirez et al. (2004), in cerebrospinal
fluid of patients with schizophrenia, the level of nitric oxide is
decreased (Ramirez et al., 2004). Concentration of substances
in cerebrospinal fluid reflects their synthesis by brain tissues. It
is therefore possible to assume a decrease in NO synthesis by
cells of the brain in schizophrenia. However, at this stage it is
not yet possible to confirm this hypothesis. The evidence base is
too small. The other known factors influencing the level of nitric
oxide in tissues and fluids of the organism are as follows: smoking
(Vleeming et al., 2002) and treatment by antipsychotics (Ramirez
et al., 2004).
NO and Neurodevelopment
In view of the possible association of schizophrenia and
metabolism of nitric oxide in the nervous tissue, the process
of neurodevelopment is of interest. There is an opinion that
disturbances of the defined localisation of NOS-containing
neurons in the process of development of the brain are associated
with vulnerability to schizophrenia (Eastwood and Harrison,
2003). Nitric oxide was detected in some neurons from the
moment of their formation, even before migration to the point
of final differentiation. From the very beginning, NO plays
a key role in formation of synapses and establishment of
local neurotransmitter links (Gibbs, 2003). Thus, movement
of such neurons to an inappropriate place leads to multiple
morphological and neurochemical alterations, which is typical
of schizophrenia (Lewis et al., 2005; Connor et al., 2011).
In addition, the influence of overproduction of nitric oxide
in prenatal and perinatal periods is also considered. It has
been shown (but only in single study) that viral infection
can cause abundant formation of nitric oxide in rat’s brain
(Fatemi et al., 2000). The increased NO synthesis in white
matter leads to damage of oligodendrocytes, demyelination of
fibers (this was observed in schizophrenics) (Uranova et al.,
2004). Increased activity of nNOS was also described at the
postnatal stage. It also leads to specific disturbances. There
was an interrelationship between NO production and NMDA
receptors, which are known as low-activity in patients with
schizophrenia (Northoff et al., 2005). The increased formation
of NO, however, does not seem to be caused by NMDA
receptors. Involvement of AMPAR receptors has been considered
as the most probable, especially because their high expression
in schizophrenics has been found (Dracheva et al., 2005; Tanda
et al., 2009). Continuous stimulation of the release of nitric
oxide results in disturbed synaptogenesis, synaptic remodeling,
and alterations of synaptic membranes (Sunico et al., 2005).
One should not underestimate the role of nitric oxide as a
free radical. Continuous stimulation of NO synthesis results
in damage of membranes of cells and mitochondrions, which
has been found in schizophrenia (Ben-Shachar and Laifenfeld,
2004). However, the role of overproduction of nitric oxide in
development of mental does not have a sufficient evidence
base as it does in neurologic pathology (multiple sclerosis,
Alzheimer’s disease) and should be confirmed by further
research.
The decreased synthesis of nitric oxide in the brain is also
discussed as a pathogenic factor of mental disorders. It has been
shown that nNOS deficiency in experiments results in cognitive
and behavioral disturbances, pathognomonic for schizophrenia
(Kirchner et al., 2004; Dec et al., 2014). Therefore, even the
migration of neurons described above may result in NO deficit
in some areas and in cognitive deficiency.
The described disturbances of synthesis and release of nitric
oxide were actively studied in the aspect of the hypothesis
according to which schizophrenia is conditioned by disturbed
neurogenesis. A paper by Oldreive et al. (2012) has shown
that an increased level of nNOS and nitric oxide deteriorates
the survival rate of Purkinje cells of the cerebellum in vitro
(Oldreive et al., 2012). We have previously mentioned that
the increased activity of nNOS was noticed in Purkinje cells
in patients with schizophrenia (Bernstein et al., 2001). It is
interesting that the harmful influence of nitric oxide on cerebellar
neurons depends on stage of their development: maturation
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of cells makes them less sensitive to NO (Oldreive et al.,
2008). The influence of nitric oxide on the development of
the hippocampus is in detail discussed in recently published
thematic reviews (Gray and Cheung, 2014; Hu and Zhu,
2014). As additional evidence of the participation of nitric
oxide in the process of neurodevelopment, experiments serve
with axotomy of motoneurons. After axotomy, the neuron
starts the reparation program that includes a dephenotyping,
creation of new synaptic afferent and efferent links. One of
the key factors in this process is NO (González-Forero and
Moreno-López, 2014). Studies have revealed that nitric oxide
can induce a proliferation of neuronal stem cells in vitro, and
at early stages—through system of ERK/MAP-kinase, and at late
stages—through guanylyl cyclase-cyclic GMP-protein kinase G
(Carreira et al., 2013). Research in this direction continues and
promises to shed light on features of neurogenesis and its key
participants.
Nitric oxide also participates in the interrelationships
between neurons and gliacytes. It was shown that increased
synthesis of NO by microglia can lead to damage of neurons
(Graber et al., 2012). iNOS is responsible for synthesis of
nitric oxide in microglia (Contestabile et al., 2012). In vitro
studies indicated NO-dependent microglial reactions in the
form of death of neurons, especially under conditions of
inflammation (Graber et al., 2012). Nevertheless, neurons
are able to secrete substances causing apoptosis of glia
for prevention of excessive synthesis of NO (Polazzi and
Contestabile, 2006). Against the background of introduced
results, conclusions that iNOS activates neurogenesis in dentate
gyrus of hippocampus are interesting (Luo et al., 2007). These
data contradict to findings of in vitro research, but at the
same time supplement evidence of the participation of NO-
synthase in processes of neurogenesis. There are still not enough
findings about the interrelationships between the activity of
iNOS and schizophrenia development. However, this enzyme
is important for understanding the role of microglia and
inflammation in disturbances of development of the central
nervous system.
Genetic Aspects of Metabolism of NO
within Schizophrenia (Table 1)
As of right now, there are associative investigations of
polymorphisms of gene of neuronal NO-synthase carried out
in patients with schizophrenia (is coded by NOS1 gene). In
one of the earliest papers (Shinkai et al., 2002), a reliable
association between the disease and the C276T polymorphism
carriage was revealed (p = 0.000007) (Shinkai et al., 2002).
Further research included several other points: Reif et al. (2006)
have established a reliable association of regulatory exon 1c
promoter polymorphism as well as nNOS-mini haplotype with
the development of schizophrenia and prefrontal functioning
(Reif et al., 2006). One of the papers by Chinese scientists where
11 polymorphisms of NOS1 gene are considered in 1705 patients
has confirmed an association of polymorphism of rs3782206
and some haplotypes from 5′ flank region of the gene with
schizophrenia (Tang et al., 2008). It is worth mentioning that
there are two papers with negative results. Okumura et al. (2009)
have carried out the analysis of seven polymorphisms of NOS1
gene (rs41279104, rs3782221, rs3782219, rs561712, rs3782206,
rs2682826, and rs6490121), but found that reliable associations
have been recognized as type I mistake in multiple calculations,
and are consequently untenable (Okumura et al., 2009). A
similar situation is described for polymorphism rs1520811 in
the Chinese population (Wang et al., 2012). Earlier Liou et al.
(2003) have also published data on the absence of an association
between CA repeat polymorphism and schizophrenia (Liou et al.,
2003). Positive results for the Japanese population have been
presented in analysis by Cui et al. (2010), who have revealed
an association of polymorphism rs41279104 with schizophrenia
development. Further, it is established that carriers of allele
A have reliably earlier age of manifestation of the disease as
compared with GG-homozygotes. In women, the influence of
genotype on tendency to disease was expressed more strongly
(Cui et al., 2010). Polymorphism rs6490121 has shown a possible
association with schizophrenia onset in GWAS, which was
confirmed by Riley et al. (2010). Functional polymorphisms
“NOS1_1d” and “NOS1_1f” have also been studied, but on
small samples of assays of brain tissue, having shown a reliable
increase in expression in schizophrenia (Silberberg et al., 2010).
NOS1 gene polymorphisms were combined with disturbance
of cognitive functions both in patients with schizophrenia
(Donohoe et al., 2009; Reif et al., 2011) and in healthy persons
(Donohoe et al., 2009; O’Donoghue et al., 2012; Rose et al., 2012).
Moreover, an essential association between the carriage of G-
allele of rs6490121 and reduction of thickness of gray matter
of the ventromedial prefrontal cortex has been noted (Rose
et al., 2012). Three investigations studied the association between
carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase
(CAPON) gene and the onset of schizophrenia across different
populations. The role of this gene consists in a disturbance
of functioning of NMDA-receptors (hypofunction) that keeps
within one of the theories of development of schizophrenia. Two
investigations have confirmed the existence of reliable linkage
disequilibrium between schizophrenia and polymorphisms of
this gene (Brzustowicz et al., 2004; Xu et al., 2005). However,
the British scientists could not replicate previous results (Puri
et al., 2006). For association of polymorphisms of gene encoding
carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase
(NOS1AP) with schizophrenia, few investigations have been
carried out. The assumption of the possible role in disease
development (Wratten et al., 2009; Delorme et al., 2010) was the
only produced result. In summary, it is worth mentioning the
meta-analysis carried out by Weber et al. (2014). The authors
studied the role of polymorphisms of genes NOS1 and NOS1AP
in schizophrenia development. Polymorphism (SNP) rs41279104
is reliably associated with disease. The carriage of the defective
allele leads to a decrease of nNOS in prefrontal cortex. The
bioinformatic analysis has also confirmed an interaction between
NOS1 and NOS1AP in increase of the tendency to the disease
(Weber et al., 2014).
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TABLE 1 | Genetic studies of nitric oxide-related enzymes’ in schizophrenia.
Gene Investigated
polymorphism(s)
Sample Control Ethnicity Results References
NOS1 C276T in exon 29 215 182 Japanese Allele frequencies of C276T differed significantly
between healthy control and schizophrenics
(p = 0.000007)
Shinkai et al., 2002
VNTR, G-84A, rs2293054,
rs1047735, rs2133681,
rs2293044
195 286 German G-84A polymorphism was linked to
schizophrenia. Haplotype VNTR(N)-G84A(A)
was associated with disease (p = 0.002)
Reif et al., 2006
rs3782206 1705 None Chinese This polymorphism and several haplotypes
derived from it has been associated with
schizophrenia, aspeccially paranoid subgroup
Tang et al., 2008
rs41279104, rs3782221,
rs3782219, rs561712,
rs3782206, rs2682826, and
rs6490121
542 519 Japanese Two SNPs were associated with schizophrenia:
rs3782219 (p allele = 0.0291) and rs3782206
(p allele = 0.0124, p genotype = 0.0490).
Authors concluded that association was the
result of type 1 error of multiple testing
(rs3782219: p allele = 0.133 and rs3782206: p
allele = 0.168)
Okumura et al., 2009
1154 1260 Two SNPs were associated with schizophrenia
rs3782219 (p allele = 0.0197) and rs3782206
(p allele = 0.0480). Authors concluded that
association was the result of type 1 error of
multiple testing (rs3782219: p allele = 0.133
and rs3782206: p allele = 0.168)
rs1520811 382 448 Chinese Results did not support a significant
association between NOS1 gene
polymorphism and schizophrenia
Wang et al., 2012
CA dinucleotide repeat
polymorphism in the
3V-UTR exon 29
198 274 Chinese The frequencies for the NOS1 genotype
(P = 0.372) and allele (P = 0.287) did not differ
significantly comparing schizophrenic patients
and controls.
Liou et al., 2003
rs41279104 720 None Japanese Significant association between this SNP and
schizophrenia was found (genotypic
p = 0.0013 and allelic p = 0.0011). Additionally,
the average of onset age in schizophrenic
patients with the A-allele was significantly
earlier than GG homozygotes (p = 0.018). This
significance was more significant for female.
Cui et al., 2010
26 29 Not reported There were no significant allelic or genotypic
differences among clinical groups
Silberberg et al., 2010
43 44 German The NOS1 schizophrenia risk genotype
rs41279104 AA/AG was associated with poor
cognition in patients
Reif et al., 2011
rs6490121 1021 626 Irish Authors detect no evidence of association with
rs6490121 in NOS1 (one-tailed p = 0.21)
Riley et al., 2010
349 230 Irish GG genotype carriers performing below IQ level
compared to other genotype groups
Donohoe et al., 2009
232 1344 German
None 54 Irish Carriers of the previously identified risk “G”
allele showed significantly lower P1 responses
(EEG-study) than non-carriers
O’Donoghue et al.,
2012
(Continued)
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TABLE 1 | Continued
Gene Investigated
polymorphism(s)
Sample Control Ethnicity Results References
None 157 Irish An a priori region-of-interest analysis identified
a significant reduction in ventromedial
prefrontal GM volume in “G” allele carriers. Risk
carriers also exhibited altered patterns of
activation in the prefrontal cortex, caudate, and
superior parietal lobe
Rose et al., 2012
CAPON CAPON region (15 SNPs) 85 232 Celtic and German 6 SNPs exhibited significant LD to
schizophrenia (nominal p < 0.05).
Brzustowicz et al.,
2004
rs1415263, rs4145621,
rs2661818
35 35 Not reported For each SNP, individuals with one or two
copies of the previously identified associated
allele were observed to have higher group
mean CAPON short-form expression than the
group of individuals homozygous for the
unassociated allele
Xu et al., 2005
CAPON region (8 SNPs) 450 450 UK-based
(English, Irish,
Scottish, Welsh)
No evidence for allelic or haplotypic association
with schizophrenia for any of the markers was
found
Puri et al., 2006
NOS1AP 60 SNPs 85 232 Celtic and German The rs12742393 was associated with
schizophrenia. That acts by enhancing
transcription factor binding and increasing
gene expression
Wratten et al., 2009
10 SNPs 72 93 French Two non-synonymous variations, V37I and
D423N were identified in two families. These
rare variations apparently segregate with the
presence of psychiatric conditions.
Delorme et al., 2010
Nitric Oxide as Potential Target for
Development of Schizophrenia Treatment
Influence of Antipsychotics on Metabolism of No
It has been shown that antipsychotics alter the metabolism of
NO in the brain. Haloperidol is able to suppress activity of
nNOS (Nel and Harvey, 2003; Zhang et al., 2012). However,
long-term administration of drugs results in hyperactivity of
this enzyme in striatum of rats (Lau et al., 2003). Authors
of this study have assumed that late alterations of nNOS
activity in neostriatum during treatment with an antipsychotic
participate in pathogenesis of late dyskinesia (tardive dyskinesia)
(Lau et al., 2003). It is worth repeating that in plasma of
schizophrenics receiving antipsychotics, the activity of nNOSwas
higher than in healthy controls (Maia-de-Oliveira et al., 2012).
These arguments call into question the existence of the uniform
concept of influence of antipsychotics on the activity of nitric
oxide. It is noted that atypical antipsychotics practically do not
influence the activity of nNOS in brain structures of patients
with schizophrenia (Tarazi et al., 2002). Besides the neuronal
isoform, antipsychotics were studied in terms of influence on
other NOS isoforms. Clozapine is able to inhibit activity of
iNOS and to decrease the level of nitric oxide in the brain and
microglial inflammation (Bringas et al., 2012; Ribeiro et al., 2013).
The influence of antipsychotics on metabolism of nitric oxide
leads to restoration of the normal function of NMDA-receptors.
However, it is not the basic link of the mechanism of action of the
medication.
Metabolism of Nitric Oxide as a Target for
Therapy of Schizophrenia
Because the considerable evidence base showing that alterations
of activity of NO are active in pathogenesis of schizophrenia,
recent attempts have been undertaken to develop the therapy
correcting disturbances of the synthesis and release of
nitric oxide. Minocycline, semisynthetic tetracycline of the
second generation, inhibiting enzyme iNOS and preventing
development of microglial inflammatory process has been quite
well studied. In double blind placebo-controlled investigations,
minocycline has shown efficiency regarding negative symptoms
of schizophrenia when added to antipsychotic therapy
(Ghanizadeh et al., 2014; Khodaie-Ardakani et al., 2014; Liu
et al., 2014). Reports about severe side effects in the carried-out
protocols have not been registered. Besides, the meta-analysis of
four randomized controlled investigations was published. In the
meta-analysis, it has been confirmed that the use of minocycline
is essentially more effective than placebo and reduces the severity
of negative symptoms, but does not influence the change of
values of scales of positive symptoms of PANSS (Oya et al., 2014).
It is worth considering that minocycline have been studied
relatively recently, and it is too early to speak to the delayed
effects of medication. Therefore, it is necessary to wait for the
long-term prospective investigations to conclude.
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L-arginine was considered as one of the perspective targets.
The carrier of L-arginine is cationic amino-acid transporter
(CAT), which can also bind with L-lysine on the competitive
base (White et al., 1982). Thus, L-lysine is considered as NO
synthesis inhibitor in CNS. Currently, there are two publications
confirming the positive role of L-lysine as an additional
preparation in treatment of schizophrenia. Results of 8-week
randomized double blind placebo-controlled investigation by
Zeinoddini et al. (2014) have been recently published, in which
Risperidone was supplemented by L-lysine. The authors noted
that the medication improves indices on the following scales of
PANSS: negative symptoms (p < 0.001), total score (p < 0.001),
general psychopathology (p < 0.001). For the scale of positive
symptoms, a difference was not noticed (p = 0.61). However,
long-term effects of L-lysine were not revealed and the sample
of patients in the investigation was also insignificant for final
conclusions (Zeinoddini et al., 2014). Besides work by Zeinoddini
et al. earlier results of a pilot investigation by Wass et al. (2011)
with similar conclusions have been published (Wass et al., 2011).
Conclusion
In the presented review of literature, recent achievements
in the study of the role of nitric oxide in pathogenesis of
schizophrenia and its treatment have been considered. Genetics
and pharmacogenetics of NO-synthase as well as of other
genes involved in the metabolism of NO are still insufficiently
investigated. For achievement of results of high evidence level,
carrying out research on increased samples with account for
ethnic origin is necessary. Certainly, it is impossible not
to take into account the exogenous factors. Possibly, their
role in the development of mental disorders will remain
incomplete for a long time. However, taking into account the
influence of the environment should be an integral part of
each investigation. The epigenetic methods, which allow for
the reflection of the influence of various factors on expression
of genes, look promising. Of no doubt, it is worth including
epigenetic methods in complex designs for receipt of multi-
sided conclusions regarding oxidative stress in pathogenesis of
schizophrenia.
Disclosure of molecular-genetic mechanisms of development
of schizophrenia becomes the first step in development of
pathogenetic therapy. The attempts, undertaken in the field
of impact on factors of oxidative stress for the purpose of
improvement of the course of the disease, clearly show positive
prospects of this approach. But without a sufficient fundamental
basis, achievement of significant results of clinical investigations
will be a failure.
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